PBLA

Panbela Therapeutics, Inc. [PBLA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PBLA Stock Summary

Top 10 Correlated Stocks

PBLA

In the News

PBLA Financial details

Company Rating
-
Market Cap
2.86M
Income
-20.75M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-0.1
Forward P/E
-
PEG
0.01
P/S
-2.13
P/B
-0.8
P/C
-
P/FCF
-0.13
Quick Ratio
0.12
Current Ratio
0.21
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-259.5
EPS next Y
-
EPS next Q
-
EPS this Y
470.4%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-99.95%
-
-
-
-
SMA20
-12.82%
SMA50
6.25%
SMA100
-2.86%
Inst Own
-
Inst Trans
-
ROA
-179%
ROE
2379%
ROC
-18.44%
Gross Margin
1334%
Oper. Margin
1926%
Profit Margin
1160%
Payout
-9%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.411-477.0
52W High
-
52W Low
-
RSI
63.14
Rel Volume
0.15
Avg Volume
733.11K
Volume
108.1K
Perf Week
29.41%
Perf Month
15.01%
Perf Quarter
15.21%
Perf Half Y
14.52%
-
-
-
-
Beta
0.78
-
-
Volatility
0.03%, 0.03%
Prev Close
30.63%
Price
0.418
Change
30.63%

Something similar

Top by Market Cap
NVDA
BRH.DE
LLY.DE
LLY.SW
MIX.JO
Same Sector
XOMA
MLND
VIFN.SW
GBCS
2142.HK
Top Correlated Stocks
0R2B.L
LBTYK
LBTYA
DHR
MAAL
Similar Market Cap
NAVB
EURA.ST
NAOV
FULO
RA7Z.F

Company Profile

Healthcare Biotechnology
  • Volume Average 733.11K
  • Market Capitalization 2.86M
  • Employee 7
  • CEO Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.
  • Headquarters Waconia,MN,US
  • IPO Date 2017-01-03
  • Website https://www.panbela.com

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.